Global immunology pioneer Argenx SE (NASDAQ:ARGX) on Monday struck a definitive agreement to purchase Forte Biosciences, Inc.
(NASDAQ:FBRX) in a substantial all-cash transaction.
Priced at $77 per share, the buyout commands a total equity value of roughly $2.2 billion, signaling a major strategic expansion for the acquiring firm.
The Driving Force: FB102 The core motivation behind this multi-billion dollar acquisition is Forte Biosciences' primary clinical program, FB102.
The first-in-class anti-CD122 antibody represents a significant addition to the buyer's pipeline, having already achieved clinical proof-of-concept in treating both vitiligo and celiac disease.
